You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLisinopril
Accession NumberDB00722  (APRD00560)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.
Structure
Thumb
Synonyms
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
[N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
Lisinopril
Lisinopril anhydrous
Lisinoprilum
External Identifiers
  • L 154826
  • MK 521
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LisinoprilTablet10 mgOralActavis Pharma Company2007-10-17Not applicableCanada
Act LisinoprilTablet20 mgOralActavis Pharma Company2007-10-17Not applicableCanada
Act LisinoprilTablet5 mgOralActavis Pharma Company2007-10-17Not applicableCanada
Auro-lisinoprilTablet5 mgOralAuro Pharma Inc2013-02-12Not applicableCanada
Auro-lisinoprilTablet10 mgOralAuro Pharma Inc2013-02-12Not applicableCanada
Auro-lisinoprilTablet20 mgOralAuro Pharma Inc2013-02-12Not applicableCanada
Dom-lisinoprilTablet5 mgOralDominion Pharmacal2008-04-16Not applicableCanada
Dom-lisinoprilTablet10 mgOralDominion Pharmacal2008-04-16Not applicableCanada
Dom-lisinoprilTablet20 mgOralDominion Pharmacal2008-04-16Not applicableCanada
Ipg-lisinoprilTablet5 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-lisinoprilTablet10 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-lisinoprilTablet20 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-lisinoprilTablet10 mgOralJamp Pharma Corporation2011-02-04Not applicableCanada
Jamp-lisinoprilTablet20 mgOralJamp Pharma Corporation2011-02-04Not applicableCanada
Jamp-lisinoprilTablet5 mgOralJamp Pharma Corporation2011-02-04Not applicableCanada
LisinoprilTablet20 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
LisinoprilTablet20 mgOralSorres Pharma Inc2009-06-222014-06-20Canada
LisinoprilTablet40 mgOralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
LisinoprilTablet5 mgOralMeliapharm Inc2008-03-122014-06-25Canada
LisinoprilTablet5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
LisinoprilTablet10 mgOralMeliapharm Inc2008-03-122014-06-25Canada
LisinoprilTablet5 mgOralSorres Pharma Inc2009-06-222014-06-20Canada
LisinoprilTablet10 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
LisinoprilTablet5 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
LisinoprilTablet20 mgOralMeliapharm Inc2008-03-122014-06-25Canada
LisinoprilTablet10 mgOralSorres Pharma Inc2009-06-222014-06-20Canada
LisinoprilTablet20 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
LisinoprilTablet10 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
Lisinopril TabletsTablet20 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Lisinopril TabletsTablet5 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Lisinopril TabletsTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Lisinopril Tablets USPTablet20 mgOralLUPIN LIMITEDNot applicableNot applicableCanada
Lisinopril Tablets USPTablet5 mgOralLUPIN LIMITEDNot applicableNot applicableCanada
Lisinopril Tablets USPTablet10 mgOralLUPIN LIMITEDNot applicableNot applicableCanada
Mar-lisinoprilTablet5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-lisinoprilTablet10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-lisinoprilTablet20 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-lisinoprilTablet10 mgOralMint Pharmaceuticals Inc2008-10-282012-08-02Canada
Mint-lisinoprilTablet20 mgOralMint Pharmaceuticals Inc2008-10-282012-08-02Canada
Mint-lisinoprilTablet5 mgOralMint Pharmaceuticals Inc2008-10-282012-08-02Canada
Mylan-lisinoprilTablet20 mgOralMylan Pharmaceuticals Ulc2007-10-17Not applicableCanada
Mylan-lisinoprilTablet5 mgOralMylan Pharmaceuticals Ulc2007-10-17Not applicableCanada
Mylan-lisinoprilTablet10 mgOralMylan Pharmaceuticals Ulc2007-10-17Not applicableCanada
Nu-lisinoprilTablet20 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-lisinoprilTablet40 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-lisinoprilTablet40 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-lisinoprilTablet5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-lisinoprilTablet5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-lisinoprilTablet10 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-lisinoprilTablet10 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-lisinoprilTablet20 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-lisinoprilTablet10 mgOralPharmascience Inc2007-10-17Not applicableCanada
PMS-lisinoprilTablet20 mgOralPharmascience Inc2007-10-17Not applicableCanada
PMS-lisinoprilTablet5 mgOralPharmascience Inc2007-10-17Not applicableCanada
PrinivilTablet5 mgOralMerck Canada Inc1990-12-31Not applicableCanada
PrinivilTablet20 mg/1OralMerck Sharp & Dohme Corp.1987-12-29Not applicableUs
PrinivilTablet2.5 mgOralMerck Canada Inc2000-01-052005-06-23Canada
PrinivilTablet10 mgOralMerck Canada Inc1990-12-31Not applicableCanada
PrinivilTablet5 mg/1OralMerck Sharp & Dohme Corp.1987-12-29Not applicableUs
PrinivilTablet20 mgOralMerck Canada Inc1990-12-31Not applicableCanada
PrinivilTablet10 mg/1OralMerck Sharp & Dohme Corp.1987-12-29Not applicableUs
Pro-lisinopril - 10Tablet10 mgOralPro Doc Limitee2008-07-03Not applicableCanada
Pro-lisinopril - 20Tablet20 mgOralPro Doc Limitee2008-07-03Not applicableCanada
Pro-lisinopril - 5Tablet5 mgOralPro Doc Limitee2008-07-03Not applicableCanada
QbrelisSolution1 mg/mLOralSilvergate Pharmaceuticals, Inc.2016-08-29Not applicableUs
Ran-lisinoprilTablet20 mgOralRanbaxy Pharmaceuticals Canada Inc.2007-10-17Not applicableCanada
Ran-lisinoprilTablet5 mgOralRanbaxy Pharmaceuticals Canada Inc.2007-10-17Not applicableCanada
Ran-lisinoprilTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.2007-10-17Not applicableCanada
Ratio-lisinopril PTablet20 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-10-172014-09-19Canada
Ratio-lisinopril PTablet5 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-10-172014-09-19Canada
Ratio-lisinopril PTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-10-172014-09-19Canada
Ratio-lisinopril ZTablet5 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-10-172014-09-19Canada
Ratio-lisinopril ZTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-10-172014-09-19Canada
Ratio-lisinopril ZTablet20 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-10-172014-09-19Canada
Riva-lisinoprilTablet5 mgOralLaboratoire Riva Inc2007-10-26Not applicableCanada
Riva-lisinoprilTablet10 mgOralLaboratoire Riva Inc2007-10-26Not applicableCanada
Riva-lisinoprilTablet20 mgOralLaboratoire Riva Inc2007-10-26Not applicableCanada
Sandoz LisinoprilTablet5 mgOralSandoz Canada Incorporated2007-10-17Not applicableCanada
Sandoz LisinoprilTablet10 mgOralSandoz Canada Incorporated2007-10-17Not applicableCanada
Sandoz LisinoprilTablet20 mgOralSandoz Canada Incorporated2007-10-17Not applicableCanada
Teva-lisinopril (type P)Tablet5 mgOralTeva Canada Limited2007-10-17Not applicableCanada
Teva-lisinopril (type P)Tablet10 mgOralTeva Canada Limited2007-10-17Not applicableCanada
Teva-lisinopril (type P)Tablet20 mgOralTeva Canada Limited2007-10-17Not applicableCanada
Teva-lisinopril (type Z)Tablet5 mgOralTeva Canada Limited2007-10-17Not applicableCanada
Teva-lisinopril (type Z)Tablet10 mgOralTeva Canada Limited2007-10-17Not applicableCanada
Teva-lisinopril (type Z)Tablet20 mgOralTeva Canada Limited2007-10-17Not applicableCanada
ZestrilTablet40 mg/1OralALMATICA PHARMA INC.2015-04-07Not applicableUs
ZestrilTablet5 mg/1OralAstra Zeneca Pharmaceuticals Lp2009-11-11Not applicableUs
ZestrilTablet40 mg/1OralAstra Zeneca Pharmaceuticals Lp2010-03-26Not applicableUs
ZestrilTablet10 mg/1OralALMATICA PHARMA INC.2015-04-07Not applicableUs
ZestrilTablet10 mg/1OralAstra Zeneca Pharmaceuticals Lp2009-08-28Not applicableUs
ZestrilTablet20 mg/1OralALMATICA PHARMA INC.2015-04-07Not applicableUs
ZestrilTablet2.5 mg/1OralAstra Zeneca Pharmaceuticals Lp2011-09-02Not applicableUs
ZestrilTablet2.5 mg/1OralALMATICA PHARMA INC.2015-04-07Not applicableUs
ZestrilTablet20 mg/1OralAstra Zeneca Pharmaceuticals Lp2009-05-13Not applicableUs
ZestrilTablet30 mg/1OralALMATICA PHARMA INC.2015-04-07Not applicableUs
ZestrilTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2011-11-09Not applicableUs
ZestrilTablet5 mg/1OralALMATICA PHARMA INC.2015-04-07Not applicableUs
ZestrilTablet30 mg/1OralAstra Zeneca Pharmaceuticals Lp2010-09-22Not applicableUs
Zestril Tab 10mgTablet10 mgOralAstrazeneca Canada Inc1994-12-31Not applicableCanada
Zestril Tab 20mgTablet20 mgOralAstrazeneca Canada Inc1994-12-31Not applicableCanada
Zestril Tab 5mgTablet5 mgOralAstrazeneca Canada Inc1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lisinopril Tablet (type P) - 10mgTablet10 mgOralApotex Inc1996-10-302001-08-02Canada
Apo-lisinopril Tablet (type P) - 20mgTablet20 mgOralApotex Inc1996-10-302001-08-02Canada
Apo-lisinopril Tablet (type P) - 40mgTablet40 mgOralApotex Inc1996-12-302001-08-02Canada
Apo-lisinopril Tablet (type P) - 5mgTablet5 mgOralApotex Inc1996-10-302001-08-02Canada
Apo-lisinopril Tablet 10 mgTablet10 mgOralApotex Inc1996-10-30Not applicableCanada
Apo-lisinopril Tablet 20 mgTablet20 mgOralApotex Inc1996-10-30Not applicableCanada
Apo-lisinopril Tablet 40 mgTablet40 mgOralApotex Inc1996-10-30Not applicableCanada
Apo-lisinopril Tablet 5 mgTablet5 mgOralApotex Inc1996-10-30Not applicableCanada
LisinoprilTablet10 mg/1OralGolden State Medical Supply, Inc.2015-01-07Not applicableUs
LisinoprilTablet40 mg/1OralAccord Healthcare Inc.2016-03-21Not applicableUs
LisinoprilTablet30 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
LisinoprilTablet, film coated30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-04-19Not applicableUs
LisinoprilTablet30 mg/1OralRanbaxy Pharmaceuticals Inc.2006-05-15Not applicableUs
LisinoprilTablet20 mg/1OralWockhardt USA LLC.2007-04-19Not applicableUs
LisinoprilTablet5 mg/1OralAidarex Pharmaceuticals LLC2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralRed Pharm Drug Inc.2005-11-17Not applicableUs
LisinoprilTablet2.5 mg/1OralSolco healthcare U.S., LLC2011-11-01Not applicableUs
LisinoprilTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2013-05-02Not applicableUs
LisinoprilTablet2.5 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-01-07Not applicableUs
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2011-09-292016-11-08Us
LisinoprilTablet10 mg/1OralMc Kesson Contract Packaging2011-09-08Not applicableUs
LisinoprilTablet20 mg/1OralA S Medication Solutions2013-02-13Not applicableUs
LisinoprilTablet5 mg/1OralMed Health Pharma, LLC2011-01-05Not applicableUs
LisinoprilTablet10 mg/1OralAmerican Health Packaging2005-09-222015-12-29Us
LisinoprilTablet2.5 mg/1OralKAISER FOUNDATION HOSPITALS2013-08-05Not applicableUs
LisinoprilTablet2.5 mg/1OralREMEDYREPACK INC.2016-08-11Not applicableUs
LisinoprilTablet20 mg/1OralLUPIN LIMITED2006-01-13Not applicableUs
LisinoprilTablet5 mg/1OralDIRECT RX2016-08-22Not applicableUs
LisinoprilTablet20 mg/1OralPreferred Pharmaceuticals Inc.2016-04-12Not applicableUs
LisinoprilTablet10 mg/1OralDIRECT RX2014-01-01Not applicableUs
LisinoprilTablet20 mg/1OralEon Labs, Inc.2015-05-23Not applicableUs
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2013-05-08Not applicableUs
LisinoprilTablet30 mg/1OralActavis Pharma, Inc.2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralAccord Healthcare Inc.2013-09-152018-01-31Us
LisinoprilTablet30 mg/1OralPhysicians Total Care, Inc.2007-04-12Not applicableUs
LisinoprilTablet40 mg/1OralInternational Laboratories, Inc.2015-05-12Not applicableUs
LisinoprilTablet2.5 mg/1OralBlenheim Pharmacal, Inc.2014-01-14Not applicableUs
LisinoprilTablet10 mg/1OralCardinal Health2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralCardinal Health2012-08-27Not applicableUs
LisinoprilTablet2.5 mg/1OralBlu Pharmaceuticals, LLC2009-02-02Not applicableUs
LisinoprilTablet10 mg/1OralCitron Pharma LLC2006-02-22Not applicableUs
LisinoprilTablet20 mg/1OralBlue Point Laboratories2002-07-012017-12-31Us
LisinoprilTablet5 mg/1OralWockhardt Limited2007-04-19Not applicableUs
LisinoprilTablet2.5 mg/1OralAurobindo Pharma Limited2006-02-22Not applicableUs
LisinoprilTablet40 mg/1OralClinical Solutions Wholesale2006-01-13Not applicableUs
LisinoprilTablet40 mg/1OralBlue Point Laboratories2014-02-04Not applicableUs
LisinoprilTablet30 mg/1OralApotex Corp.2002-10-09Not applicableUs
LisinoprilTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-20Not applicableUs
LisinoprilTablet20 mg/1OralProficient Rx LP2002-07-01Not applicableUs
LisinoprilTablet5 mg/1OralReady Meds2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralCamber Pharmaceuticals Inc.2013-11-15Not applicableUs
LisinoprilTablet40 mg/1OralMed Vantx, Inc.2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralKeltman Pharmaceuticals Inc.2010-12-10Not applicableUs
LisinoprilTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-11-01Not applicableUs
LisinoprilTablet10 mg/1OralSafecor Health, LLC2014-10-01Not applicableUs
LisinoprilTablet10 mg/1OralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
LisinoprilTablet10 mg/1OralA S Medication Solutions2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralUnit Dose Services2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralExelan Pharmaceuticals Inc.2014-03-15Not applicableUs
LisinoprilTablet2.5 mg/1OralWest Ward Pharmaceuticals Corp2013-02-132016-02-18Us
LisinoprilTablet5 mg/1OralClinical Solutions Wholesale, Llc2006-01-13Not applicableUs
LisinoprilTablet10 mg/1OralTYA Pharmaceuticals2002-07-012017-11-30Us
LisinoprilTablet2.5 mg/1OralLupin Pharmaceuticals, Inc.2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralA S Medication Solutions2016-04-27Not applicableUs
LisinoprilTablet2.5 mg/1OralEon Labs, Inc.2002-07-012017-09-30Us
LisinoprilTablet10 1/1OralNorthwind Pharmaceuticals, LLC2014-11-17Not applicableUs
LisinoprilTablet40 mg/1OralMylan Pharmaceuticals Inc.2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralH.J. Harkins Company, Inc.2005-11-17Not applicableUs
LisinoprilTablet20 mg/1OralMajor Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralInternational Labs, Inc.2012-02-202016-10-13Us
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2009-08-192016-11-01Us
LisinoprilTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2015-05-21Not applicableUs
LisinoprilTablet20 mg/1OralCardinal Health2012-10-052016-10-13Us
LisinoprilTablet5 mg/1OralInternational Laboratories, Inc.2008-02-01Not applicableUs
LisinoprilTablet10 mg/1OralRebel Distributors Corp2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralCardinal Health2013-12-23Not applicableUs
LisinoprilTablet5 mg/1OralA S Medication Solutions2006-01-13Not applicableUs
LisinoprilTablet40 mg/1OralWest Ward Pharmaceuticals Corp2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralMylan Pharmaceuticals Inc.2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2013-06-24Not applicableUs
LisinoprilTablet20 mg/1OralQualitest Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
LisinoprilTablet30 mg/1OralAccord Healthcare Inc.2013-09-152017-08-31Us
LisinoprilTablet5 mg/1OralCardinal Health2009-12-18Not applicableUs
LisinoprilTablet40 mg/1OralInternational Laboratories, Inc.2008-02-01Not applicableUs
LisinoprilTablet10 mg/1OralSTAT Rx USA LLC2005-11-17Not applicableUs
LisinoprilTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2015-03-23Not applicableUs
LisinoprilTablet30 mg/1OralBlu Pharmaceuticals, LLC2009-02-02Not applicableUs
LisinoprilTablet2.5 mg/1OralClinical Solutions Wholesale2006-01-13Not applicableUs
LisinoprilTablet30 mg/1OralBlue Point Laboratories2014-02-042017-09-30Us
LisinoprilTablet2.5 mg/1OralApotex Corp.2008-06-26Not applicableUs
LisinoprilTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2016-03-21Not applicableUs
LisinoprilTablet20 mg/1OralDIRECT RX2014-01-01Not applicableUs
LisinoprilTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-01Not applicableUs
LisinoprilTablet40 mg/1Oralbryant ranch prepack2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralTYA Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralRx Change Co.2014-11-12Not applicableUs
LisinoprilTablet20 mg/1OralAmerican Health Packaging2013-12-23Not applicableUs
LisinoprilTablet30 mg/1OralSolco healthcare U.S., LLC2011-11-01Not applicableUs
LisinoprilTablet5 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
LisinoprilTablet10 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-01-07Not applicableUs
LisinoprilTablet30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-02-15Not applicableUs
LisinoprilTablet30 mg/1OralA S Medication Solutions2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralMed Health Pharma, LLC2011-01-05Not applicableUs
LisinoprilTablet5 mg/1OralLiberty Pharmaceuticals, Inc.2007-04-19Not applicableUs
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2016-09-08Not applicableUs
LisinoprilTablet30 mg/1OralExelan Pharmaceuticals Inc.2014-03-15Not applicableUs
LisinoprilTablet20 mg/1OralIVAX Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2016-07-19Not applicableUs
LisinoprilTablet2.5 mg/1OralLUPIN LIMITED2006-01-13Not applicableUs
LisinoprilTablet2.5 mg/1OralUnit Dose Services2011-11-01Not applicableUs
LisinoprilTablet30 mg/1OralLupin Pharmaceuticals, Inc.2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2016-11-01Not applicableUs
LisinoprilTablet40 mg/1OralEon Labs, Inc.2002-07-012017-11-30Us
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2012-12-31Not applicableUs
LisinoprilTablet10 mg/1OralActavis Pharma, Inc.2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
LisinoprilTablet10 mg/1OralMajor Pharmaceuticals2015-06-15Not applicableUs
LisinoprilTablet10 mg/1OralPhysicians Total Care, Inc.2005-07-25Not applicableUs
LisinoprilTablet5 mg/1OralUnit Dose Services2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralBlenheim Pharmacal, Inc.2009-12-16Not applicableUs
LisinoprilTablet10 mg/1OralCardinal Health2005-09-22Not applicableUs
LisinoprilTablet40 mg/1OralCardinal Health2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2013-09-19Not applicableUs
LisinoprilTablet30 mg/1OralWockhardt Limited2007-04-19Not applicableUs
LisinoprilTablet30 mg/1OralAurobindo Pharma Limited2006-02-22Not applicableUs
LisinoprilTablet20 mg/1OralHikma Pharmaceutical2013-08-22Not applicableUs
LisinoprilTablet10 mg/1OralAccord Healthcare Inc.2016-03-21Not applicableUs
LisinoprilTablet2.5 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
LisinoprilTablet, film coated5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-04-19Not applicableUs
LisinoprilTablet10 mg/1OralRanbaxy Pharmaceuticals Inc.2002-07-02Not applicableUs
LisinoprilTablet2.5 mg/1OralWockhardt USA LLC.2007-04-19Not applicableUs
LisinoprilTablet40 mg/1OralAidarex Pharmaceuticals LLC2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralContract Pharmacy Services Pa2010-08-12Not applicableUs
LisinoprilTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralPreferred Pharmaceuticals Inc.2015-08-28Not applicableUs
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2016-09-29Not applicableUs
LisinoprilTablet30 mg/1OralREMEDYREPACK INC.2011-06-212016-10-13Us
LisinoprilTablet20 mg/1OralLife Line Home Care Services, Inc.2010-08-12Not applicableUs
LisinoprilTablet5 mg/1OralA S Medication Solutions2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralMylan Institutional Inc.2002-08-01Not applicableUs
LisinoprilTablet20 mg/1OralCardinal Health2006-01-13Not applicableUs
LisinoprilTablet40 mg/1OralCardinal Health2012-08-27Not applicableUs
LisinoprilTablet5 mg/1OralBlu Pharmaceuticals, LLC2009-02-02Not applicableUs
LisinoprilTablet20 mg/1OralCitron Pharma LLC2006-02-22Not applicableUs
LisinoprilTablet40 mg/1OralBlue Point Laboratories2014-02-042017-11-30Us
LisinoprilTablet20 mg/1OralGolden State Medical Supply, Inc.2015-01-07Not applicableUs
LisinoprilTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-09-15Not applicableUs
LisinoprilTablet40 mg/1OralSt Marys Medical Park Pharmacy2002-07-01Not applicableUs
LisinoprilTablet, film coated40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-04-19Not applicableUs
LisinoprilTablet5 mg/1Oralbryant ranch prepack2005-11-17Not applicableUs
LisinoprilTablet40 mg/1OralWockhardt USA LLC.2007-04-19Not applicableUs
LisinoprilTablet30 mg/1OralAidarex Pharmaceuticals LLC2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralRed Pharm Drug Inc.2002-07-01Not applicableUs
LisinoprilTablet5 mg/1OralSolco healthcare U.S., LLC2011-11-01Not applicableUs
LisinoprilTablet5 mg/1OralPreferred Pharmaceuticals, Inc.2013-12-03Not applicableUs
LisinoprilTablet10 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralLake Erie Medical Quality Care Products LLC2012-03-27Not applicableUs
LisinoprilTablet20 mg/1OralMc Kesson Contract Packaging2011-09-09Not applicableUs
LisinoprilTablet10 mg/1OralA S Medication Solutions2013-02-13Not applicableUs
LisinoprilTablet10 mg/1OralMed Health Pharma, LLC2011-01-05Not applicableUs
LisinoprilTablet20 mg/1OralAmerican Health Packaging2005-09-222015-12-29Us
LisinoprilTablet40 mg/1OralKAISER FOUNDATION HOSPITALS2008-11-03Not applicableUs
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2016-08-15Not applicableUs
LisinoprilTablet30 mg/1OralLUPIN LIMITED2006-01-13Not applicableUs
LisinoprilTablet10 mg/1OralA S Medication Solutions2014-05-16Not applicableUs
LisinoprilTablet5 mg/1OralWest Ward Pharmaceuticals Corp2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralPreferred Pharmaceuticals, Inc.2011-11-01Not applicableUs
LisinoprilTablet30 mg/1OralEon Labs, Inc.2015-08-19Not applicableUs
LisinoprilTablet40 mg/1OralREMEDYREPACK INC.2013-05-13Not applicableUs
LisinoprilTablet2.5 mg/1OralQualitest Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
LisinoprilTablet5 mg/1OralAccord Healthcare Inc.2013-09-152017-10-31Us
LisinoprilTablet20 mg/1OralCardinal Health2005-09-22Not applicableUs
LisinoprilTablet20 mg/1OralInternational Laboratories, Inc.2015-05-12Not applicableUs
LisinoprilTablet5 mg/1OralBlenheim Pharmacal, Inc.2015-02-19Not applicableUs
LisinoprilTablet5 mg/1OralInternational Labs, Inc.2012-02-202016-10-13Us
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2009-07-302016-11-01Us
LisinoprilTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2015-05-23Not applicableUs
LisinoprilTablet40 mg/1OralCardinal Health2002-07-012016-10-13Us
LisinoprilTablet2.5 mg/1OralInternational Laboratories, Inc.2008-02-01Not applicableUs
LisinoprilTablet20 mg/1OralRebel Distributors Corp2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralWockhardt Limited2007-04-19Not applicableUs
LisinoprilTablet5 mg/1OralAurobindo Pharma Limited2006-02-22Not applicableUs
LisinoprilTablet2.5 mg/1OralHikma Pharmaceutical2013-08-22Not applicableUs
LisinoprilTablet2.5 mg/1OralCarilion Materials Management2002-07-012017-09-30Us
LisinoprilTablet40 mg/1OralApotex Corp.2008-01-22Not applicableUs
LisinoprilTablet30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-20Not applicableUs
LisinoprilTablet5 mg/1OralProficient Rx LP2011-11-01Not applicableUs
LisinoprilTablet10 mg/1OralReady Meds2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralCamber Pharmaceuticals Inc.2013-11-15Not applicableUs
LisinoprilTablet10 mg/1OralMed Vantx, Inc.2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralLegacy Pharmaceutical Packaging2010-10-01Not applicableUs
LisinoprilTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-11-01Not applicableUs
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2010-09-162016-10-13Us
LisinoprilTablet40 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
LisinoprilTablet20 mg/1OralA S Medication Solutions2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralUnit Dose Services2002-07-01Not applicableUs
LisinoprilTablet5 mg/1OralExelan Pharmaceuticals Inc.2014-03-15Not applicableUs
LisinoprilTablet2.5 mg/1OralIVAX Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralClinical Solutions Wholesale, Llc2006-01-13Not applicableUs
LisinoprilTablet2.5 mg/1OralBlue Point Laboratories2016-09-07Not applicableUs
LisinoprilTablet5 mg/1OralLupin Pharmaceuticals, Inc.2006-01-13Not applicableUs
LisinoprilTablet40 mg/1OralA S Medication Solutions2016-04-29Not applicableUs
LisinoprilTablet10 mg/1OralEon Labs, Inc.2002-07-012017-11-30Us
LisinoprilTablet20 mg/1OralNorthwind Pharmaceuticals, LLC2014-11-21Not applicableUs
LisinoprilTablet30 mg/1OralMylan Pharmaceuticals Inc.2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralAidarex Pharmaceuticals LLC2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralMajor Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralCardinal Health2015-06-15Not applicableUs
LisinoprilTablet5 mg/1OralNorthwind Pharmaceuticals, LLC2014-07-30Not applicableUs
LisinoprilTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-20Not applicableUs
LisinoprilTablet40 mg/1OralREMEDYREPACK INC.2016-09-12Not applicableUs
LisinoprilTablet20 mg/1OralCardinal Health2013-12-23Not applicableUs
LisinoprilTablet2.5 mg/1OralA S Medication Solutions2014-05-162018-01-31Us
LisinoprilTablet20 mg/1OralWest Ward Pharmaceuticals Corp2013-02-13Not applicableUs
LisinoprilTablet5 mg/1OralMylan Pharmaceuticals Inc.2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2013-05-28Not applicableUs
LisinoprilTablet30 mg/1OralQualitest Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
LisinoprilTablet40 mg/1OralAccord Healthcare Inc.2013-07-302017-11-30Us
LisinoprilTablet40 mg/1OralCardinal Health2009-12-18Not applicableUs
LisinoprilTablet30 mg/1OralInternational Laboratories, Inc.2008-02-01Not applicableUs
LisinoprilTablet20 mg/1OralSTAT Rx USA LLC2007-04-19Not applicableUs
LisinoprilTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2005-11-17Not applicableUs
LisinoprilTablet10 mg/1OralProficient Rx LP2006-01-13Not applicableUs
LisinoprilTablet40 mg/1OralBlu Pharmaceuticals, LLC2009-02-02Not applicableUs
LisinoprilTablet5 mg/1OralClinical Solutions Wholesale2006-01-13Not applicableUs
LisinoprilTablet10 mg/1OralBlue Point Laboratories2015-07-06Not applicableUs
LisinoprilTablet5 mg/1OralApotex Corp.2008-02-18Not applicableUs
LisinoprilTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2016-03-21Not applicableUs
LisinoprilTablet5 mg/1OralDIRECT RX2015-01-01Not applicableUs
LisinoprilTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1Oralbryant ranch prepack2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralTYA Pharmaceuticals2006-01-13Not applicableUs
LisinoprilTablet2.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralAmerican Health Packaging2013-12-23Not applicableUs
LisinoprilTablet40 mg/1OralSolco healthcare U.S., LLC2011-11-01Not applicableUs
LisinoprilTablet5 mg/1OralPreferred Pharmaceuticals Inc.2015-08-20Not applicableUs
LisinoprilTablet5 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-01-07Not applicableUs
LisinoprilTablet30 mg/1OralUnit Dose Services2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralPreferred Pharmaceuticals Inc.2015-10-29Not applicableUs
LisinoprilTablet40 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-03-15Not applicableUs
LisinoprilTablet2.5 mg/1OralREMEDYREPACK INC.2011-07-132016-10-28Us
LisinoprilTablet2.5 mg/1OralMc Kesson Contract Packaging2011-09-01Not applicableUs
LisinoprilTablet40 mg/1OralA S Medication Solutions2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralMylan Institutional Inc.2002-08-01Not applicableUs
LisinoprilTablet40 mg/1OralExelan Pharmaceuticals Inc.2014-03-15Not applicableUs
LisinoprilTablet40 mg/1OralIVAX Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2016-08-01Not applicableUs
LisinoprilTablet5 mg/1OralLUPIN LIMITED2006-01-13Not applicableUs
LisinoprilTablet5 mg/1OralUnit Dose Services2016-03-21Not applicableUs
LisinoprilTablet40 mg/1OralLupin Pharmaceuticals, Inc.2006-01-13Not applicableUs
LisinoprilTablet5 mg/1OralPreferred Pharmaceuticals Inc.2016-11-07Not applicableUs
LisinoprilTablet2.5 mg/1OralEon Labs, Inc.2015-12-21Not applicableUs
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2013-07-05Not applicableUs
LisinoprilTablet20 mg/1OralActavis Pharma, Inc.2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
LisinoprilTablet20 mg/1OralMajor Pharmaceuticals2015-06-15Not applicableUs
LisinoprilTablet20 mg/1OralPhysicians Total Care, Inc.2007-09-17Not applicableUs
LisinoprilTablet2.5 mg/1OralREMEDYREPACK INC.2013-03-18Not applicableUs
LisinoprilTablet40 mg/1OralBlenheim Pharmacal, Inc.2010-05-20Not applicableUs
LisinoprilTablet2.5 mg/1OralCardinal Health2006-01-13Not applicableUs
LisinoprilTablet5 mg/1OralCardinal Health2012-08-27Not applicableUs
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2013-05-202016-11-01Us
LisinoprilTablet2.5 mg/1OralCitron Pharma LLC2006-02-22Not applicableUs
LisinoprilTablet40 mg/1OralAurobindo Pharma Limited2006-02-22Not applicableUs
LisinoprilTablet2.5 mg/1OralGolden State Medical Supply, Inc.2015-01-07Not applicableUs
LisinoprilTablet20 mg/1OralAccord Healthcare Inc.2016-03-21Not applicableUs
LisinoprilTablet5 mg/1OralSt Marys Medical Park Pharmacy2013-05-16Not applicableUs
LisinoprilTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-04-19Not applicableUs
LisinoprilTablet20 mg/1OralRanbaxy Pharmaceuticals Inc.2002-07-02Not applicableUs
LisinoprilTablet5 mg/1OralWockhardt USA LLC.2007-04-19Not applicableUs
LisinoprilTablet20 mg/1OralAidarex Pharmaceuticals LLC2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralContract Pharmacy Services Pa2002-08-02Not applicableUs
LisinoprilTablet2.5 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
LisinoprilTablet10 mg/1OralAccord Healthcare Inc.2013-09-152017-09-30Us
LisinoprilTablet10 mg/1OralCardinal Health2009-12-18Not applicableUs
LisinoprilTablet10 mg/1OralInternational Laboratories, Inc.2015-05-12Not applicableUs
LisinoprilTablet20 mg/1OralBlenheim Pharmacal, Inc.2015-02-19Not applicableUs
LisinoprilTablet40 mg/1OralCardinal Health2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralCardinal Health2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralBlu Pharmaceuticals, LLC2009-02-02Not applicableUs
LisinoprilTablet30 mg/1OralCitron Pharma LLC2006-02-22Not applicableUs
LisinoprilTablet10 mg/1OralBlue Point Laboratories2014-02-042017-12-31Us
LisinoprilTablet30 mg/1OralGolden State Medical Supply, Inc.2015-01-07Not applicableUs
LisinoprilTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-09-15Not applicableUs
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2015-07-22Not applicableUs
LisinoprilTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-02Not applicableUs
LisinoprilTablet10 mg/1Oralbryant ranch prepack2002-07-01Not applicableUs
LisinoprilTablet30 mg/1OralWockhardt USA LLC.2007-04-19Not applicableUs
LisinoprilTablet5 mg/1OralRx Change Co.2014-11-18Not applicableUs
LisinoprilTablet5 mg/1OralAmerican Health Packaging2013-12-23Not applicableUs
LisinoprilTablet10 mg/1OralSolco healthcare U.S., LLC2011-11-01Not applicableUs
LisinoprilTablet20 mg/1OralPreferred Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-01-07Not applicableUs
LisinoprilTablet20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-07-19Not applicableUs
LisinoprilTablet40 mg/1OralMc Kesson Contract Packaging2011-09-16Not applicableUs
LisinoprilTablet40 mg/1OralA S Medication Solutions2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralMed Health Pharma, LLC2011-01-05Not applicableUs
LisinoprilTablet40 mg/1OralAmerican Health Packaging2005-09-222015-12-05Us
LisinoprilTablet20 mg/1OralKAISER FOUNDATION HOSPITALS2008-11-03Not applicableUs
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2016-08-19Not applicableUs
LisinoprilTablet40 mg/1OralLUPIN LIMITED2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralA S Medication Solutions2014-05-162018-01-31Us
LisinoprilTablet10 mg/1OralWest Ward Pharmaceuticals Corp2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralProficient Rx LP2011-11-01Not applicableUs
LisinoprilTablet40 mg/1OralEon Labs, Inc.2015-06-09Not applicableUs
LisinoprilTablet40 mg/1OralREMEDYREPACK INC.2013-05-14Not applicableUs
LisinoprilTablet5 mg/1OralQualitest Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2013-02-26Not applicableUs
LisinoprilTablet2.5 mg/1OralActavis Pharma, Inc.2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
LisinoprilTablet5 mg/1OralMajor Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralPhysicians Total Care, Inc.2004-08-25Not applicableUs
LisinoprilTablet40 mg/1OralREMEDYREPACK INC.2009-09-222016-11-01Us
LisinoprilTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2015-06-09Not applicableUs
LisinoprilTablet5 mg/1OralCardinal Health2012-10-052016-10-13Us
LisinoprilTablet5 mg/1OralCardinal Health2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralRebel Distributors Corp2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralWockhardt Limited2007-04-19Not applicableUs
LisinoprilTablet10 mg/1OralAurobindo Pharma Limited2006-02-22Not applicableUs
LisinoprilTablet5 mg/1OralHikma Pharmaceutical2013-08-22Not applicableUs
LisinoprilTablet2.5 mg/1OralAccord Healthcare Inc.2016-03-21Not applicableUs
LisinoprilTablet30 mg/1OralAmerican Health Packaging2015-10-01Not applicableUs
LisinoprilTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-20Not applicableUs
LisinoprilTablet2.5 mg/1OralRanbaxy Pharmaceuticals Inc.2002-07-02Not applicableUs
LisinoprilTablet20 mg/1OralReady Meds2002-07-01Not applicableUs
LisinoprilTablet30 mg/1OralCamber Pharmaceuticals Inc.2013-11-15Not applicableUs
LisinoprilTablet10 mg/1OralContract Pharmacy Services Pa2010-08-12Not applicableUs
LisinoprilTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralLegacy Pharmaceutical Packaging, Llc2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-11-01Not applicableUs
LisinoprilTablet40 mg/1OralREMEDYREPACK INC.2011-04-202016-10-13Us
LisinoprilTablet20 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
LisinoprilTablet2.5 mg/1OralA S Medication Solutions2006-01-13Not applicableUs
LisinoprilTablet5 mg/1OralMylan Institutional Inc.2002-08-01Not applicableUs
LisinoprilTablet10 mg/1OralExelan Pharmaceuticals Inc.2014-03-15Not applicableUs
LisinoprilTablet5 mg/1OralIVAX Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralClinical Solutions Wholesale, Llc2006-01-13Not applicableUs
LisinoprilTablet10 mg/1OralPreferred Pharmaceuticals Inc.2016-06-10Not applicableUs
LisinoprilTablet10 mg/1OralLupin Pharmaceuticals, Inc.2006-01-13Not applicableUs
LisinoprilTablet40 mg/1OralA S Medication Solutions2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralEon Labs, Inc.2002-07-012017-12-31Us
LisinoprilTablet2.5 mg/1OralAmerican Health Packaging2014-06-02Not applicableUs
LisinoprilTablet40 mg/1OralMedsource Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
LisinoprilTablet20 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralUnit Dose Services2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralCardinal Health2015-06-15Not applicableUs
LisinoprilTablet40 mg/1OralNorthwind Pharmaceuticals, LLC2015-03-10Not applicableUs
LisinoprilTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-20Not applicableUs
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2016-10-04Not applicableUs
LisinoprilTablet5 mg/1OralCardinal Health2013-12-23Not applicableUs
LisinoprilTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2016-10-25Not applicableUs
LisinoprilTablet10 mg/1OralWest Ward Pharmaceuticals Corp2013-02-13Not applicableUs
LisinoprilTablet10 mg/1OralMylan Pharmaceuticals Inc.2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2013-05-28Not applicableUs
LisinoprilTablet40 mg/1OralQualitest Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet30 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
LisinoprilTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-02-15Not applicableUs
LisinoprilTablet2.5 mg/1OralCardinal Health2009-12-18Not applicableUs
LisinoprilTablet20 mg/1OralInternational Laboratories, Inc.2008-02-01Not applicableUs
LisinoprilTablet40 mg/1OralSTAT Rx USA LLC2007-04-19Not applicableUs
LisinoprilTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralProficient Rx LP2006-01-13Not applicableUs
LisinoprilTablet2.5 mg/1OralCamber Pharmaceuticals Inc.2013-11-15Not applicableUs
LisinoprilTablet10 mg/1OralClinical Solutions Wholesale2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralBlue Point Laboratories2015-07-06Not applicableUs
LisinoprilTablet10 mg/1OralApotex Corp.2008-04-17Not applicableUs
LisinoprilTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2016-03-21Not applicableUs
LisinoprilTablet40 mg/1OralDIRECT RX2015-01-01Not applicableUs
LisinoprilTablet30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2002-07-01Not applicableUs
LisinoprilTablet5 mg/1OralTYA Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2006-01-13Not applicableUs
LisinoprilTablet10 mg/1OralWockhardt USA LLC.2007-04-19Not applicableUs
LisinoprilTablet10 mg/1OralAidarex Pharmaceuticals LLC2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralRed Pharm Drug Inc.2002-07-02Not applicableUs
LisinoprilTablet40 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralPreferred Pharmaceuticals Inc.2015-10-28Not applicableUs
LisinoprilTablet20 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-07-012017-12-31Us
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2011-05-192016-11-15Us
LisinoprilTablet5 mg/1OralMc Kesson Contract Packaging2011-09-07Not applicableUs
LisinoprilTablet30 mg/1OralA S Medication Solutions2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralMed Health Pharma, LLC2011-01-05Not applicableUs
LisinoprilTablet5 mg/1OralAmerican Health Packaging2005-09-222015-12-29Us
LisinoprilTablet30 mg/1OralIVAX Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2016-08-01Not applicableUs
LisinoprilTablet10 mg/1OralLUPIN LIMITED2006-01-13Not applicableUs
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2016-10-18Not applicableUs
LisinoprilTablet5 mg/1OralPreferred Pharmaceuticals Inc.2016-04-12Not applicableUs
LisinoprilTablet20 mg/1OralAidarex Pharmaceuticals LLC2013-02-13Not applicableUs
LisinoprilTablet10 mg/1OralEon Labs, Inc.2015-05-21Not applicableUs
LisinoprilTablet2.5 mg/1OralREMEDYREPACK INC.2013-05-08Not applicableUs
LisinoprilTablet40 mg/1OralActavis Pharma, Inc.2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
LisinoprilTablet40 mg/1OralMajor Pharmaceuticals2015-06-15Not applicableUs
LisinoprilTablet5 mg/1OralPhysicians Total Care, Inc.2008-04-10Not applicableUs
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2012-11-07Not applicableUs
LisinoprilTablet5 mg/1OralBlenheim Pharmacal, Inc.2014-02-28Not applicableUs
LisinoprilTablet5 mg/1OralCardinal Health2006-01-13Not applicableUs
LisinoprilTablet10 mg/1OralCardinal Health2012-08-27Not applicableUs
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2013-02-282016-10-21Us
LisinoprilTablet5 mg/1OralCitron Pharma LLC2006-02-22Not applicableUs
LisinoprilTablet5 mg/1OralBlue Point Laboratories2014-02-042017-11-30Us
LisinoprilTablet5 mg/1OralGolden State Medical Supply, Inc.2015-01-07Not applicableUs
LisinoprilTablet30 mg/1OralAccord Healthcare Inc.2016-03-21Not applicableUs
LisinoprilTablet10 mg/1OralSt Marys Medical Park Pharmacy2002-07-01Not applicableUs
LisinoprilTablet, film coated20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-04-19Not applicableUs
LisinoprilTablet40 mg/1OralRanbaxy Pharmaceuticals Inc.2002-07-02Not applicableUs
LisinoprilTablet5 mg/1OralEon Labs, Inc.2002-07-012017-11-30Us
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2013-05-16Not applicableUs
LisinoprilTablet10 mg/1OralQualitest Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
LisinoprilTablet20 mg/1OralAccord Healthcare Inc.2013-09-152018-01-31Us
LisinoprilTablet20 mg/1OralCardinal Health2009-12-18Not applicableUs
LisinoprilTablet5 mg/1OralInternational Laboratories, Inc.2015-05-12Not applicableUs
LisinoprilTablet10 mg/1OralBlenheim Pharmacal, Inc.2015-02-19Not applicableUs
LisinoprilTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2005-11-17Not applicableUs
LisinoprilTablet2.5 mg/1OralCardinal Health2012-10-05Not applicableUs
LisinoprilTablet20 mg/1OralBlu Pharmaceuticals, LLC2009-02-02Not applicableUs
LisinoprilTablet40 mg/1OralCitron Pharma LLC2006-02-22Not applicableUs
LisinoprilTablet2.5 mg/1OralBlue Point Laboratories2014-07-312017-12-31Us
LisinoprilTablet40 mg/1OralGolden State Medical Supply, Inc.2015-01-07Not applicableUs
LisinoprilTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-09-15Not applicableUs
LisinoprilTablet10 mg/1OralREMEDYREPACK INC.2015-12-23Not applicableUs
LisinoprilTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-01Not applicableUs
LisinoprilTablet20 mg/1Oralbryant ranch prepack2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralTYA Pharmaceuticals2006-01-13Not applicableUs
LisinoprilTablet10 mg/1OralRx Change Co.2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralAmerican Health Packaging2013-12-23Not applicableUs
LisinoprilTablet20 mg/1OralSolco healthcare U.S., LLC2011-11-01Not applicableUs
LisinoprilTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2013-12-03Not applicableUs
LisinoprilTablet40 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-01-07Not applicableUs
LisinoprilTablet40 mg/1OralLake Erie Medical Quality Care Products LLC2012-03-27Not applicableUs
LisinoprilTablet5 mg/1OralUnit Dose Services2016-03-21Not applicableUs
LisinoprilTablet30 mg/1OralMed Health Pharma, LLC2011-01-05Not applicableUs
LisinoprilTablet30 mg/1OralAmerican Health Packaging2014-12-152015-12-29Us
LisinoprilTablet5 mg/1OralKAISER FOUNDATION HOSPITALS2008-11-03Not applicableUs
LisinoprilTablet40 mg/1OralREMEDYREPACK INC.2016-09-06Not applicableUs
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2011-09-292016-11-15Us
LisinoprilTablet40 mg/1OralA S Medication Solutions2014-05-162017-11-30Us
LisinoprilTablet20 mg/1OralWest Ward Pharmaceuticals Corp2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralProficient Rx LP2011-11-01Not applicableUs
LisinoprilTablet20 mg/1OralLupin Pharmaceuticals, Inc.2006-01-13Not applicableUs
LisinoprilTablet40 mg/1OralREMEDYREPACK INC.2016-10-31Not applicableUs
LisinoprilTablet30 mg/1OralEon Labs, Inc.2002-07-012017-11-30Us
LisinoprilTablet20 mg/1OralREMEDYREPACK INC.2013-03-20Not applicableUs
LisinoprilTablet5 mg/1OralActavis Pharma, Inc.2002-07-01Not applicableUs
LisinoprilTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
LisinoprilTablet5 mg/1OralMajor Pharmaceuticals2015-06-15Not applicableUs
LisinoprilTablet2.5 mg/1OralPhysicians Total Care, Inc.2009-02-16Not applicableUs
LisinoprilTablet30 mg/1OralREMEDYREPACK INC.2011-07-192016-10-28Us
LisinoprilTablet10 mg/1OralBlenheim Pharmacal, Inc.2009-12-16Not applicableUs
LisinoprilTablet5 mg/1OralCardinal Health2005-09-22Not applicableUs
LisinoprilTablet10 mg/1OralCardinal Health2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralRebel Distributors Corp2008-02-01Not applicableUs
LisinoprilTablet40 mg/1OralWockhardt Limited2007-04-19Not applicableUs
LisinoprilTablet20 mg/1OralAurobindo Pharma Limited2006-02-22Not applicableUs
LisinoprilTablet10 mg/1OralHikma Pharmaceutical2013-08-22Not applicableUs
LisinoprilTablet5 mg/1OralAccord Healthcare Inc.2016-03-21Not applicableUs
LisinoprilTablet20 mg/1OralSt Marys Medical Park Pharmacy2002-07-01Not applicableUs
LisinoprilTablet, film coated2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-04-19Not applicableUs
LisinoprilTablet5 mg/1OralRanbaxy Pharmaceuticals Inc.2002-07-02Not applicableUs
LisinoprilTablet40 mg/1OralReady Meds2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralCamber Pharmaceuticals Inc.2013-11-15Not applicableUs
LisinoprilTablet10 mg/1OralContract Pharmacy Services Pa2002-07-02Not applicableUs
LisinoprilTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet10 mg/1OralPreferred Pharmaceuticals Inc.2015-08-28Not applicableUs
LisinoprilTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-11-01Not applicableUs
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2011-03-292016-10-19Us
LisinoprilTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
LisinoprilTablet5 mg/1OralA S Medication Solutions2013-02-13Not applicableUs
LisinoprilTablet10 mg/1OralMylan Institutional Inc.2002-08-01Not applicableUs
LisinoprilTablet20 mg/1OralExelan Pharmaceuticals Inc.2014-03-15Not applicableUs
LisinoprilTablet10 mg/1OralIVAX Pharmaceuticals, Inc.2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralClinical Solutions Wholesale, Llc2006-01-13Not applicableUs
LisinoprilTablet20 mg/1OralPreferred Pharmaceuticals Inc.2016-06-14Not applicableUs
LisinoprilTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2002-07-01Not applicableUs
LisinoprilTablet20 mg/1OralMed Vantx, Inc.2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralPd Rx Pharmaceuticals, Inc.2002-07-02Not applicableUs
LisinoprilTablet2.5 mg/1OralDispensing Solutions, Inc.2005-11-17Not applicableUs
LisinoprilTablet10 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
LisinoprilTablet20 mg/1OralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
LisinoprilTablet10 mg/1OralA S Medication Solutions2002-07-012017-11-30Us
LisinoprilTablet20 mg/1OralUnit Dose Services2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralClinical Solutions Wholesale, Llc2006-01-13Not applicableUs
LisinoprilTablet10 mg/301OralNorthwind Pharmaceuticals2014-05-20Not applicableUs
LisinoprilTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-20Not applicableUs
LisinoprilTablet20 mg/1OralProficient Rx LP2015-05-23Not applicableUs
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2015-10-08Not applicableUs
LisinoprilTablet10 mg/1OralA S Medication Solutions2016-04-25Not applicableUs
LisinoprilTablet5 mg/1OralWest Ward Pharmaceuticals Corp2013-02-13Not applicableUs
LisinoprilTablet20 mg/1OralMylan Pharmaceuticals Inc.2002-07-01Not applicableUs
LisinoprilTablet5 mg/1OralREMEDYREPACK INC.2014-04-04Not applicableUs
LisinoprilTablet10 mg/1OralMajor Pharmaceuticals2002-07-01Not applicableUs
LisinoprilTablet40 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
LisinoprilTablet40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-02-15Not applicableUs
LisinoprilTablet10 mg/1OralCardinal Health2012-10-052016-10-13Us
LisinoprilTablet10 mg/1OralInternational Laboratories, Inc.2008-02-01Not applicableUs
LisinoprilTablet5 mg/1OralRebel Distributors Corp2002-07-01Not applicableUs
LisinoprilTablet2.5 mg/1OralWockhardt Limited2007-04-19Not applicableUs
LisinoprilTablet20 mg/1OralProficient Rx LP2006-01-13Not applicableUs
LisinoprilTablet5 mg/1OralCamber Pharmaceuticals Inc.2013-11-15Not applicableUs
LisinoprilTablet20 mg/1OralClinical Solutions Wholesale2006-01-13Not applicableUs
LisinoprilTablet30 mg/1OralBlue Point Laboratories2015-07-06Not applicableUs
LisinoprilTablet20 mg/1OralApotex Corp.2008-06-25Not applicableUs
LisinoprilTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-11-01Not applicableUs
LisinoprilTablet20 mg/1OralProficient Rx LP2002-07-01Not applicableUs
Lisinopril 10mgTablet10 mg/1OralMcKesson Contract Packaging2013-08-01Not applicableUs
Lisinopril 2.5mgTablet2.5 mg/1OralMcKesson Contract Packaging2013-08-01Not applicableUs
Lisinopril 20mgTablet20 mg/1OralMcKesson Contract Packaging2013-08-01Not applicableUs
Lisinopril 40mgTablet40 mg/1OralMcKesson Contract Packaging2013-08-01Not applicableUs
Lisinopril 5mgTablet5 mg/1OralMcKesson Contract Packaging2013-08-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcebitorGlaxoSmithKline
AceminAstraZeneca
AcerbonAstraZeneca
Acinoprilsanofi-aventis
BellisinRanbaxy
BioprilBiochem
DaprilMedochemie
FibsolSigma
FisoprilSanofi-Aventis
HiprilMicro Labs
LinoprilKlinger (Brazil)
LisiprilHexal (Czech Republic), Orion (Finland)
NopertenDexa (Indonesia)
PresitenMagnachem
RanolipRanbaxy
RanoprilRanbaxy
RantexBiotech
SinoprenRanbaxy
SinoprilEczacibasi (Russia)
TensoprilMerck
Brand mixtures
NameLabellerIngredients
Apo-lisinopril/hctzApotex Inc
Ava-lisinopril HctAvanstra Inc
Lisinopril and HctzNorthwind Pharmaceuticals, LLC
Lisinopril and HydrochlorothiazideIVAX Pharmaceuticals, Inc.
Lisinopril and HydrochlorthiazideREMEDYREPACK INC.
Lisinopril With HydrochlorothiazidePd Rx Pharmaceuticals, Inc.
Lisinopril/hctz (type Z)Sanis Health Inc
Lisnopril/hctz (type P)Sanis Health Inc
LytensoprilPhysician Therapeutics Llc
Lytensopril-90Physician Therapeutics Llc
Mylan-lisinopril HctzMylan Pharmaceuticals Ulc
Ntp-lisinopril/hctz (type P)Teva Canada Limited
Ntp-lisinopril/hctz (type Z)Teva Canada Limited
Nu-lisinopril/hctzNu Pharm Inc
PrinzideMerck Canada Inc
Sandoz Lisinopril HctSandoz Canada Incorporated
Teva-lisinopril/hctz (type P)Teva Canada Limited
Teva-lisinopril/hctz (type Z)Teva Canada Limited
ZestoreticAstra Zeneca Pharmaceuticals Lp
Zestoretic Tab 10/12.5mgAstrazeneca Canada Inc
Zestoretic Tab 20/12.5mgAstrazeneca Canada Inc
Zestoretic Tab 20/25mgAstrazeneca Canada Inc
SaltsNot Available
Categories
UNIIE7199S1YWR
CAS number83915-83-7
WeightAverage: 405.4879
Monoisotopic: 405.226371117
Chemical FormulaC21H31N3O5
InChI KeyRLAWWYSOJDYHDC-BZSNNMDCSA-N
InChI
InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
IUPAC Name
(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid
SMILES
NCCCC[[email protected]](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[[email protected]]1C(O)=O
Pharmacology
IndicationFor the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or β-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.
Structured Indications
PharmacodynamicsLisinopril is an orally active ACE inhibitor that antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of lisinopril by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Lisinopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Lisinopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
Angiotensin-converting enzyme 2Proteinyes
inhibitor
HumanQ9BYF1 details
Related Articles
AbsorptionApproximately 25%, but widely variable between individuals (6 to 60%) in all doses tested (5-80 mg); absorption is unaffected by food
Volume of distributionNot Available
Protein bindingLisinopril does not appear to be bound to serum proteins other than ACE.
Metabolism

Does not undergo metabolism, excreted unchanged in urine.

Route of eliminationLisinopril does not undergo metabolism and is excreted unchanged entirely in the urine.
Half lifeEffective half life of accumulation following multiple dosing is 12 hours.
Clearance
  • 10 L/h [child weighting 30 kg receiving doses of 0.1 to 0.2 mg/kg]
ToxicitySymptoms of overdose include severe hypotension, electrolyte disturbances, and renal failure. LD50= 2000 mg/kg(orally in rat). Most frequent adverse effects include headache, dizziness, cough, fatigue and diarrhea.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Lisinopril Action PathwayDrug actionSMP00150
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Lisinopril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Lisinopril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Lisinopril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Lisinopril is combined with Aceclofenac.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Lisinopril.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Lisinopril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Lisinopril.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Lisinopril.Experimental
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Lisinopril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Lisinopril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Lisinopril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Lisinopril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Lisinopril.Approved, Illicit, Investigational
AlprenololLisinopril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Lisinopril.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lisinopril.Experimental
AmifostineLisinopril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Lisinopril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Lisinopril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Lisinopril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Lisinopril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Lisinopril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Lisinopril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Lisinopril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Lisinopril is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Lisinopril is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Antipyrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Lisinopril.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Lisinopril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Lisinopril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Lisinopril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Lisinopril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Lisinopril is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Lisinopril.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Lisinopril.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Lisinopril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Lisinopril.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Lisinopril.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Azapropazone.Withdrawn
AzathioprineLisinopril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lisinopril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Lisinopril.Experimental
BarbitalBarbital may increase the hypotensive activities of Lisinopril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Lisinopril.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Lisinopril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Lisinopril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Lisinopril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Benoxaprofen.Withdrawn
BepridilLisinopril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Lisinopril.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Lisinopril.Approved
BethanidineBethanidine may increase the hypotensive activities of Lisinopril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Lisinopril is combined with Betulinic Acid.Investigational
BimatoprostLisinopril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Lisinopril.Approved
BoceprevirThe serum concentration of Lisinopril can be decreased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Lisinopril.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Lisinopril.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lisinopril.Approved
BretyliumThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Lisinopril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Lisinopril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Lisinopril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bupivacaine.Approved, Investigational
BupranololLisinopril may increase the hypotensive activities of Bupranolol.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Lisinopril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Lisinopril.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Lisinopril.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Lisinopril.Experimental
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Lisinopril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Lisinopril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Lisinopril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Captopril.Approved
CarbamazepineThe metabolism of Lisinopril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Lisinopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Lisinopril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Lisinopril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Lisinopril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Lisinopril is combined with Celecoxib.Approved, Investigational
CeliprololLisinopril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Lisinopril.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Lisinopril.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Lisinopril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Lisinopril.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Lisinopril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Lisinopril.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Lisinopril.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Lisinopril.Approved, Investigational
CiprofloxacinLisinopril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Lisinopril.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Lisinopril.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Lisinopril.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lisinopril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Lisinopril.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Lisinopril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Lisinopril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Lisinopril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Lisinopril.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Lisinopril.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Lisinopril.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Lisinopril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Lisinopril is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Lisinopril.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Lisinopril.Approved
CryptenamineLisinopril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Lisinopril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Lisinopril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Lisinopril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Lisinopril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Lisinopril is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lisinopril.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Lisinopril.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Lisinopril.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Lisinopril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Lisinopril.Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Lisinopril.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Lisinopril.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Lisinopril.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Lisinopril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Lisinopril.Investigational
DeserpidineLisinopril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Desflurane.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Lisinopril.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Lisinopril.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lisinopril.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Lisinopril.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Lisinopril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Lisinopril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Lisinopril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Lisinopril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Lisinopril.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Lisinopril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lisinopril.Approved
DihydralazineLisinopril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Lisinopril.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Lisinopril.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Lisinopril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Lisinopril.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Lisinopril.Approved, Investigational, Vet Approved
DorzolamideLisinopril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Lisinopril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Lisinopril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Lisinopril.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Lisinopril.Approved, Investigational
DrospirenoneLisinopril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Lisinopril is combined with Droxicam.Approved
DuloxetineLisinopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Lisinopril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Lisinopril.Approved
E6201The risk or severity of adverse effects can be increased when Lisinopril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ebselen.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Lisinopril.Approved
EfonidipineLisinopril may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Lisinopril.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Lisinopril.Approved, Vet Approved
EnalaprilatLisinopril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Lisinopril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Lisinopril.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Lisinopril.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Lisinopril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Lisinopril.Approved
EpoprostenolLisinopril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lisinopril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lisinopril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Lisinopril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Lisinopril.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Lisinopril.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Lisinopril.Approved, Vet Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Lisinopril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Lisinopril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Lisinopril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Lisinopril.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Lisinopril.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Lisinopril.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Lisinopril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Lisinopril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lisinopril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etofenamate.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Lisinopril.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Lisinopril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Lisinopril.Approved
exisulindThe risk or severity of adverse effects can be increased when Lisinopril is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Lisinopril.Approved
FelodipineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Fenbufen.Approved
FenoldopamLisinopril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Fenoprofen.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Lisinopril.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Lisinopril.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Lisinopril.Approved
FimasartanThe risk or severity of adverse effects can be increased when Lisinopril is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Lisinopril.Approved
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Lisinopril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lisinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Lisinopril.Approved, Vet Approved
GarlicThe serum concentration of Lisinopril can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Lisinopril.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Lisinopril.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Lisinopril.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Lisinopril.Withdrawn
GuanabenzGuanabenz may increase the hypotensive activities of Lisinopril.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Lisinopril.Approved
GuanethidineLisinopril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Lisinopril.Approved
HalothaneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
HexamethoniumLisinopril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Lisinopril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Lisinopril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Lisinopril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Lisinopril.Approved
HydralazineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Lisinopril.Approved, Vet Approved
HydroflumethiazideLisinopril may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Lisinopril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Lisinopril.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Lisinopril.Approved
IloprostIloprost may increase the hypotensive activities of Lisinopril.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Lisinopril.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Lisinopril.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Lisinopril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Indapamide.Approved
IndenololLisinopril may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Lisinopril.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Lisinopril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Indoprofen.Withdrawn
IndoraminLisinopril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Lisinopril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Lisinopril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lisinopril.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Lisinopril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Lisinopril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Lisinopril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Lisinopril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Lisinopril.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Lisinopril.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Kebuzone.Experimental
KetanserinLisinopril may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Lisinopril.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Lisinopril.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Lisinopril.Approved
LacidipineLisinopril may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Lisinopril.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Lisinopril.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Lisinopril.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lisinopril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Lisinopril.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Lisinopril.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Lisinopril.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Lisinopril.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Lisinopril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Lisinopril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Levobupivacaine.Approved
LevodopaLisinopril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Lisinopril.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Lisinopril.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Lisinopril is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Lisinopril.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Lisinopril.Approved
LofexidineLisinopril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Lisinopril.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lisinopril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Lisinopril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Lisinopril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lisinopril is combined with Lumiracoxib.Approved, Investigational
MacitentanLisinopril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Lisinopril is combined with Magnesium salicylate.Approved
ManidipineLisinopril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Lisinopril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Lisinopril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Lisinopril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Lisinopril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Lisinopril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Lisinopril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Lisinopril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Lisinopril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Lisinopril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Lisinopril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Lisinopril.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lisinopril.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lisinopril.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Lisinopril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Lisinopril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Lisinopril.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Lisinopril.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Lisinopril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Lisinopril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Lisinopril.Approved, Investigational
MetyrosineLisinopril may increase the hypotensive activities of Metyrosine.Approved
MibefradilLisinopril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Lisinopril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Lisinopril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Lisinopril.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Lisinopril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Lisinopril.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Lisinopril.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Lisinopril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Lisinopril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Lisinopril.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Lisinopril.Approved, Investigational
MoxonidineLisinopril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lisinopril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Lisinopril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Naftifine.Approved
NaftopidilLisinopril may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Lisinopril.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Lisinopril.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Lisinopril is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Lisinopril.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Lisinopril.Approved
NepafenacThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Lisinopril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Lisinopril.Approved
NicorandilNicorandil may increase the hypotensive activities of Lisinopril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Lisinopril is combined with Niflumic Acid.Approved
NiguldipineLisinopril may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Lisinopril.Approved, Investigational
NilvadipineLisinopril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Lisinopril.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Lisinopril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Lisinopril.Approved
NitrendipineLisinopril may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Lisinopril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Lisinopril.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Lisinopril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Lisinopril.Approved
ObinutuzumabLisinopril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Lisinopril.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Lisinopril.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lisinopril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Olsalazine.Approved
OmapatrilatLisinopril may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Lisinopril.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Lisinopril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Lisinopril.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Oxaprozin.Approved
OxprenololLisinopril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Lisinopril.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Lisinopril.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Lisinopril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Lisinopril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Lisinopril.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Lisinopril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Lisinopril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
PentoliniumLisinopril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Lisinopril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Lisinopril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Lisinopril.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Lisinopril.Approved
PhenoxybenzamineLisinopril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Lisinopril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Lisinopril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Lisinopril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Lisinopril.Approved
PinacidilLisinopril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pipamperone.Approved
PiretanidePiretanide may increase the hypotensive activities of Lisinopril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Lisinopril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Lisinopril is combined with Piroxicam.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Lisinopril.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Lisinopril.Withdrawn
PolythiazideLisinopril may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Lisinopril.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Lisinopril.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Lisinopril.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Lisinopril.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Lisinopril.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Lisinopril.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Lisinopril.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Lisinopril is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Lisinopril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Lisinopril.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Lisinopril.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Lisinopril.Approved
PTC299The risk or severity of adverse effects can be increased when Lisinopril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Lisinopril.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Lisinopril.Approved
QuinineQuinine may increase the hypotensive activities of Lisinopril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Lisinopril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Lisinopril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Lisinopril.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Lisinopril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Lisinopril.Approved
RescinnamineLisinopril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Lisinopril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Lisinopril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Lisinopril.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Lisinopril.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Lisinopril.Approved, Investigational
RilmenidineLisinopril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Lisinopril.Approved
RisperidoneLisinopril may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Lisinopril.Approved, Investigational
RituximabLisinopril may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Lisinopril.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Lisinopril is combined with Rofecoxib.Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Lisinopril.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Lisinopril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Lisinopril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Lisinopril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Lisinopril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lisinopril.Experimental
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Lisinopril.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Lisinopril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Lisinopril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Lisinopril.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Lisinopril.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Lisinopril is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Lisinopril.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Lisinopril.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Lisinopril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Lisinopril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Lisinopril.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Lisinopril.Approved, Investigational
SitaxentanLisinopril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Lisinopril.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Lisinopril.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Lisinopril.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Lisinopril.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Lisinopril.Experimental
SpiraprilLisinopril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Lisinopril.Approved
SRT501The risk or severity of adverse effects can be increased when Lisinopril is combined with SRT501.Investigational
St. John's WortThe metabolism of Lisinopril can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Lisinopril is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Lisinopril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Lisinopril.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Lisinopril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Lisinopril.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Lisinopril.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lisinopril.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Lisinopril.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Lisinopril.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Lisinopril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lisinopril.Approved, Investigational
TemocaprilLisinopril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Lisinopril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Teriflunomide.Approved
TerlipressinLisinopril may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Lisinopril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Lisinopril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tiaprofenic acid.Approved
TiboloneLisinopril may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Lisinopril.Approved
TicrynafenLisinopril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Lisinopril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Lisinopril.Approved
TipranavirThe serum concentration of Lisinopril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Lisinopril.Approved
TolazolineLisinopril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Lisinopril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Lisinopril.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Lisinopril.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Lisinopril.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Lisinopril.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Lisinopril.Approved
TranilastThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lisinopril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Lisinopril.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Lisinopril.Approved
TravoprostTravoprost may increase the hypotensive activities of Lisinopril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Lisinopril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Lisinopril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Lisinopril.Approved
TrichlormethiazideLisinopril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinLisinopril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanLisinopril may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Lisinopril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Lisinopril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Lisinopril.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Lisinopril.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Lisinopril.Approved
UnoprostoneLisinopril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Lisinopril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Lisinopril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Lisinopril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Lisinopril.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Lisinopril.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Lisinopril.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Lisinopril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Lisinopril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Lisinopril.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Lisinopril.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Lisinopril.Approved, Investigational
VinpocetineLisinopril may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Lisinopril.Approved
XylometazolineLisinopril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Lisinopril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Lisinopril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Lisinopril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Lisinopril is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Lisinopril is combined with Zomepirac.Withdrawn
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of lisinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of lisinopril.
  • Lisinopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Take without regard to meals.
References
Synthesis Reference

Vincenzo Cannata, Valeriano Merli, Stefano Saguatti, “Process for the production of alkoxycarbonyldipeptides intermediates in the synthesis of the lisinopril.” U.S. Patent US6166217, issued September, 1972.

US6166217
General References
  1. Abdelmalek MF, Douglas DD: Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema. Dig Dis Sci. 1997 Apr;42(4):847-50. [PubMed:9125659 ]
  2. Hasslacher C: Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. J Diabetes Complications. 1996 May-Jun;10(3):136-8. [PubMed:8807458 ]
  3. Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P: Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care. 2009 Sep;32(9):1684-8. doi: 10.2337/dc09-0429. Epub 2009 Jun 5. [PubMed:19502542 ]
  4. Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. [PubMed:6253826 ]
External Links
ATC CodesC09AA03C09BB03C09BA03C10BX07
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelDownload (267 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6426
Blood Brain Barrier-0.8815
Caco-2 permeable-0.7605
P-glycoprotein substrateSubstrate0.6515
P-glycoprotein inhibitor INon-inhibitor0.9512
P-glycoprotein inhibitor IINon-inhibitor0.969
Renal organic cation transporterNon-inhibitor0.8574
CYP450 2C9 substrateNon-substrate0.8793
CYP450 2D6 substrateNon-substrate0.7622
CYP450 3A4 substrateNon-substrate0.725
CYP450 1A2 substrateNon-inhibitor0.8999
CYP450 2C9 inhibitorNon-inhibitor0.9708
CYP450 2D6 inhibitorNon-inhibitor0.9653
CYP450 2C19 inhibitorNon-inhibitor0.8266
CYP450 3A4 inhibitorNon-inhibitor0.907
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9821
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9389
BiodegradationNot ready biodegradable0.6844
Rat acute toxicity1.8723 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9641
hERG inhibition (predictor II)Non-inhibitor0.8708
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lek pharmaceuticals d d
  • Lupin ltd
  • Mylan pharmaceuticals inc
  • Ranbaxy pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Wockhardt ltd
  • Merck research laboratories div merck co inc
  • Astrazeneca uk ltd
Packagers
Dosage forms
FormRouteStrength
TabletOral40 mg
TabletOral10 1/1
TabletOral10 mg/301
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
TabletOral
Kit
TabletOral10 mg
TabletOral2.5 mg
TabletOral20 mg
TabletOral5 mg
SolutionOral1 mg/mL
Prices
Unit descriptionCostUnit
Prinivil 90 20 mg tablet Bottle111.71USD bottle
Prinzide 30 20-12.5 mg tablet Bottle45.99USD bottle
Prinivil 30 2.5 mg tablet Bottle22.48USD bottle
Lisinopril 100% powder21.6USD g
Zestril 40 mg tablet2.53USD tablet
Zestril 30 mg tablet2.41USD tablet
Prinivil 40 mg tablet2.23USD tablet
Zestoretic 20-25 mg tablet2.01USD tablet
Zestoretic 20-12.5 mg tablet2.0USD tablet
Prinzide 20-25 mg tablet1.98USD tablet
Zestoretic 10-12.5 mg tablet1.89USD tablet
Zestoretic 10-12.5 tablet1.75USD tablet
Lisinopril 30 mg tablet1.53USD tablet
Lisinopril 40 mg tablet1.44USD tablet
Prinzide 20-12.5 mg tablet1.38USD tablet
Prinzide 10-12.5 mg tablet1.37USD tablet
Zestril 20 mg tablet1.37USD tablet
Zestril 10 mg tablet1.33USD tablet
Zestoretic 20-25 tablet1.28USD tablet
Zestril 5 mg tablet1.28USD tablet
Zestoretic 20-12.5 tablet1.26USD tablet
Lisinopril 20 mg tablet1.09USD tablet
Prinivil 20 mg tablet1.05USD tablet
Zestril 2.5 mg tablet1.04USD tablet
Lisinopril 10 mg tablet1.01USD tablet
Prinivil 10 mg tablet1.01USD tablet
Lisinopril 5 mg tablet0.99USD tablet
Prinivil 5 mg tablet0.96USD tablet
Apo-Lisinopril 20 mg Tablet0.71USD tablet
Co Lisinopril 20 mg Tablet0.71USD tablet
Mylan-Lisinopril 20 mg Tablet0.71USD tablet
Novo-Lisinopril (Type P) 20 mg Tablet0.71USD tablet
Novo-Lisinopril (Type Z) 20 mg Tablet0.71USD tablet
Pms-Lisinopril 20 mg Tablet0.71USD tablet
Ran-Lisinopril 20 mg Tablet0.71USD tablet
Ratio-Lisinopril P 20 mg Tablet0.71USD tablet
Ratio-Lisinopril Z 20 mg Tablet0.71USD tablet
Sandoz Lisinopril 20 mg Tablet0.71USD tablet
Lisinopril 2.5 mg tablet0.65USD tablet
Apo-Lisinopril 10 mg Tablet0.59USD tablet
Co Lisinopril 10 mg Tablet0.59USD tablet
Mylan-Lisinopril 10 mg Tablet0.59USD tablet
Novo-Lisinopril (Type P) 10 mg Tablet0.59USD tablet
Novo-Lisinopril (Type Z) 10 mg Tablet0.59USD tablet
Pms-Lisinopril 10 mg Tablet0.59USD tablet
Ran-Lisinopril 10 mg Tablet0.59USD tablet
Ratio-Lisinopril P 10 mg Tablet0.59USD tablet
Ratio-Lisinopril Z 10 mg Tablet0.59USD tablet
Sandoz Lisinopril 10 mg Tablet0.59USD tablet
Apo-Lisinopril 5 mg Tablet0.49USD tablet
Co Lisinopril 5 mg Tablet0.49USD tablet
Mylan-Lisinopril 5 mg Tablet0.49USD tablet
Novo-Lisinopril (Type P) 5 mg Tablet0.49USD tablet
Novo-Lisinopril (Type Z) 5 mg Tablet0.49USD tablet
Pms-Lisinopril 5 mg Tablet0.49USD tablet
Ran-Lisinopril 5 mg Tablet0.49USD tablet
Ratio-Lisinopril P 5 mg Tablet0.49USD tablet
Ratio-Lisinopril Z 5 mg Tablet0.49USD tablet
Sandoz Lisinopril 5 mg Tablet0.49USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility9.7E+004 mg/LMERCK INDEX (1996)
logP-1.01MERCK INDEX (1996); pH 7
pKa2.5 (at 25 °C)MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.216 mg/mLALOGPS
logP-1.2ALOGPS
logP-3.1ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.17ChemAxon
pKa (Strongest Basic)10.21ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area132.96 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity107.37 m3·mol-1ChemAxon
Polarizability43.5 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-0a4r-0194100000-d9a47a283478b88bb101View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-001i-9040000000-8d6d4ae6ba18da11e336View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-001i-9000000000-77e20f7eb799eea58ab0View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Alpha-amino acid amide
  • L-alpha-amino acid
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Aralkylamine
  • Amino fatty acid
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A: Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54. Epub 2007 Jun 27. [PubMed:17618628 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]
  5. Tellez-Sanz R, Garcia-Fuentes L, Baron C: Calorimetric analysis of lisinopril binding to angiotensin I-converting enzyme. FEBS Lett. 1998 Feb 13;423(1):75-80. [PubMed:9506845 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin-13 with high efficiency. May be an important regulator of heart function.(Microbial infection) Acts as a receptor for SARS coronavirus/SARS-CoV and human coronavirus NL63/HCoV-NL63.
Gene Name:
ACE2
Uniprot ID:
Q9BYF1
Molecular Weight:
92462.4 Da
References
  1. Parish RC, Miller LJ: Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Saf. 1992 Jan-Feb;7(1):14-31. [PubMed:1536695 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [PubMed:15618677 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23